Apollo Life Science's Human Proteins Lead To Improved Cancer Treatment by Boosting Stem Cell Growth
Apollo Life Sciences Ltd announced that initial studies showed two of its human proteins outperform competitor proteins in stimulating faster growth in numbers of blood-producing stem cells, which are mainly used to generate white blood cells for chemotherapy patients.
"This means that Apollo's proteins potentially offer cancer patients the chance to increase their rate of chemotherapy, leading to improved and even lifesaving outcomes," Dr Greg Russell-Jones, Apollo's Science Director, said.
A new study undertaken by Apollo showed that two of its human proteins (hcx(TM)) are up to 53% more effective than similar proteins which competitors produce from non-human cells (p-value less than 0.00021). In the series of in vitro experiments, CD34- positive haematopoietic stem cells enriched from umbilical cord blood were cultured with a medium containing Apollo's fully G-CSF and SCF (granulocyte-colony stimulating factor and stem cell factor) with the same proteins produced from bacteria by competitors. Viable cells were counted at the end of seven days.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.